U-VUE Biomarker Datasheet - HLA-DR
|Alternative Name:||MHC class II antigen DRA|
|Main cell types:||Antigen-presenting cells (APCs)|
|Subcellular Location:||Plasma membrane|
|Positive control:||Tonsil, Spleen|
Human leukocyte antigen (HLA) complex encodes the major histocompatibility complex (MHC). HLA-DR is the main isotype of 3 isotype (-DR, -DP, -DQ) responsible for presentation of antigens to T cells and B cells. Often, HLA-DR is used as a marker indicating the presence of antigen-presenting cells.
IHC: Anti-HLA-DR antibody [TAL 1B5] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.
IHC: Anti-HLA-DR antibody conjugate [TAL 1B5] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.
ISP: Anti-HLA-DR antibody conjugate [TAL 1B5] staining normal tonsil FFPE tissue (green). Hematoxylin counterstain in blue.
- Roher, Alex E et al. “Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy.” PloS one, vol. 8,3 (2013): e59735. DOI: 10.1371/journal.pone.0059735
- He, Yi-feng et al. “High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time.” PloS one, vol. 8,12 e79769. 6 Dec. 2013 DOI: 10.1371/journal.pone.0079769
- Dunne, Margaret R et al. “HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.” Cancer immunology, immunotherapy : CII, vol. 66,7 (2017): 841-850. DOI: 10.1007/s00262-017-1983-1
Each lot of antibody conjugate reagent is quality control tested on positive control tissue and reviewed by Ultivue’s Pathology and Biomarker Analytics group to ensure appropriate staining patterns and signal intensity.
This U-VUE Antibody Conjugate is for Research Use Only. Not for Diagnostic purposes.